Welcome to innoVitro – Your choice for high throughput contractility testing of cardiac and other human iPSC-derived cells!
innoVitro is a Contract Research Organisation based in Germany with core competences in measurement and analysis of cellular forces, in particular cardiac contraction of human iPSC-derived cardiomyocytes. The analysis is based on the FLEXcyte technology, a cutting-edge modern high throughput technique for the 21st century that overcame the limited cardiac contractility approaches of the Langendorff Heart, thus opened the door for fast and reliable cardiac risk assessment conducted for drug discovery as well as preclinical safety, toxicity and efficacy departments.
FLEXcyte Service – Let us do your contractility research
We offer flexible contractility services - compound and / or cell type characterization - conducted for pre-clinical safety, toxicology and efficacy departments but also basic research. The studies are flexible in their design and include a comprehensive set of measureable parameters to support your in-house project and save your time and resources.
FLEXcyte 96 Technology - Flexibility is key for a pro-maturation effect
Standard cultivation methods do not provide the flexible environment cells would experience naturally. The FLEXcyte plates, produced by innoVitro, mimic the mechanical conditions of real biological tissue via hyperelastic silicone membranes that form a biohybrid with the cardiac tissue. This natural environment supports the development of a mature phenotype of cultured human iPSC-derived cardiomyocytes in vitro. The pro-maturation effect, in combination with the higher throughput design, makes the FLEXcyte 96 the perfect tool for contractility research in the pre-clinical field.